ATI RN
Principles of Pharmacology Questions
Question 1 of 5
During a medication review session, a patient states, “I do not know why I am taking all of these pills.” Based on this piece of subjective data, which problem will the nurse identify?
Correct Answer: B
Rationale: The correct answer is B: Knowledge. The patient's statement indicates a lack of understanding about their medications. This can lead to non-adherence, mismanagement, or harm. Pain (A), fatigue (C), and anxiety (D) are not directly related to the patient's lack of knowledge about their medications. Pain and fatigue may be addressed separately, while anxiety may be a result of the patient's confusion but is not the primary issue identified by the nurse in this scenario.
Question 2 of 5
The research nurse is meeting with a patient and determines, based on the assessment, that the patient meets inclusion criteria for clinical research. The patient agrees to participate in the clinical trial. The nurse advises the patient that which member of the health care team has the responsibility to explain the study and respond to questions?
Correct Answer: D
Rationale: The correct answer is D: Health care provider. The health care provider, typically the physician or principal investigator, is responsible for explaining the study details and addressing any questions the patient may have. As the primary individual overseeing the patient's care and treatment, the health care provider is best equipped to provide comprehensive information about the research study. Registered nurses (choice A) may assist in conveying information, but the ultimate responsibility lies with the health care provider. Pharmacists (choice B) play a crucial role in medication management but are not typically involved in explaining research studies. Research associates (choice C) may aid in study coordination but do not have the same level of medical expertise as the health care provider.
Question 3 of 5
The foundation of clinical trials, Good Clinical Practice, is a helpful resource for nurses. The nurse is correct in choosing Good Clinical Practice as a reference for standards in which areas? (Select all that apply.)
Correct Answer: A
Rationale: The correct answer is A: Design. Good Clinical Practice (GCP) provides guidelines for the design of clinical trials to ensure ethical conduct, data integrity, and participant safety. It covers aspects such as study protocol development, participant selection, and informed consent procedures. Monitoring and auditing (B) are also covered by GCP, but they focus on oversight rather than design. Analyses (C) and reporting (D) are more related to data management and interpretation, which are not the primary focus of GCP's design guidelines. Therefore, the nurse should choose GCP as a reference for standards in the design of clinical trials.
Question 4 of 5
The nurse is reviewing a patient’s list of medications and notes that several have the highest abuse potential. According to US standards, the highest potential for abuse of drugs with accepted medical uses is found in drugs included in which schedule?
Correct Answer: A
Rationale: The correct answer is A: II. Schedule II drugs in the US have the highest potential for abuse among drugs with accepted medical uses. This is because they have a high potential for psychological and physical dependence. These drugs have strict regulations for prescribing and dispensing to minimize the risk of abuse. Schedule III, IV, and V drugs have lower abuse potential compared to Schedule II drugs. Schedule III drugs have a moderate to low potential for abuse, while Schedule IV and V drugs have even lower potential for abuse and are considered to have accepted medical uses with lower risk of dependence.
Question 5 of 5
Which components of pharmacokinetics does the nurse need to understand before administering a drug? (Select all that apply.)
Correct Answer: A
Rationale: The correct answer is A because drugs with a smaller volume of distribution tend to stay in the bloodstream longer, leading to a longer half-life. This is important for determining dosing intervals. Option B is incorrect because oral drugs are usually absorbed through passive diffusion or active transport, not pinocytosis. Option C is incorrect because patients with kidney disease may actually have more protein-binding sites, leading to potential drug accumulation. Option D is incorrect because rapid absorption typically increases the bioavailability of the drug, not decreases it.